Jonathan Wolleben
Stock Analyst at Citizens JMP
(4.89)
# 295
Out of 5,078 analysts
695
Total ratings
52.2%
Success rate
22.5%
Average return
Main Sectors:
Stocks Rated by Jonathan Wolleben
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SGMT Sagimet Biosciences | Reiterated: Buy | $12 → $27 | $9.58 | +181.84% | 22 | Oct 1, 2026 | |
| PHVS Pharvaris | Reiterated: Buy | $74 → $79 | $31.41 | +151.51% | 35 | Sep 9, 2026 | |
| PTGX Protagonist Therapeutics | Reiterated: Buy | $165 → $170 | $138.43 | +22.81% | 38 | Aug 31, 2026 | |
| SION Sionna Therapeutics | Downgraded: Hold | n/a | $3.60 | - | 2 | Aug 10, 2026 | |
| GPCR Structure Therapeutics | Reiterated: Buy | $113 → $110 | $21.19 | +419.11% | 26 | Aug 7, 2026 | |
| BMEA Biomea Fusion | Reiterated: Buy | $9 → $7 | $0.6001 | +1,066.47% | 2 | Aug 6, 2026 | |
| MIRM Mirum Pharmaceuticals | Reiterated: Buy | $146 → $137 | $80.39 | +70.42% | 33 | Aug 6, 2026 | |
| RYTM Rhythm Pharmaceuticals | Reiterated: Buy | $152 → $160 | $89.27 | +79.23% | 22 | Aug 5, 2026 | |
| ANNX Annexon | Initiated Coverage: Sell | $3 | $3.75 | -20.00% | 1 | Jul 21, 2026 | |
| MDGL Madrigal Pharmaceuticals | Reiterated: Buy | $745 → $739 | $434.24 | +70.18% | 62 | Jul 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $55 | $9.75 | +464.10% | 45 | Jun 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $14 → $11 | $2.12 | +418.87% | 81 | May 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $170 → $150 | $45.15 | +232.23% | 28 | May 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $12 → $11 | $3.47 | +217.00% | 2 | May 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $26 → $25 | $1.87 | +1,236.90% | 3 | May 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $61 → $86 | $48.50 | +77.32% | 4 | May 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $25 → $28 | $7.65 | +266.01% | 49 | May 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $8 | $1.29 | +520.16% | 42 | Mar 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $6.50 | - | 63 | Feb 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $8 → $11 | $4.22 | n/a | 17 | Oct 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $18 | $2.35 | n/a | 41 | Oct 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $120 → $32 | $1.54 | n/a | 7 | Oct 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $19 | $6.30 | n/a | 27 | May 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $16.64 | n/a | 42 | Apr 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $24 | $30.86 | n/a | 1 | May 12, 2023 |
Sagimet Biosciences
Oct 1, 2026
Reiterated: Buy
Price Target: $12 → $27
Current: $9.58
Upside: +181.84%
Pharvaris
Sep 9, 2026
Reiterated: Buy
Price Target: $74 → $79
Current: $31.41
Upside: +151.51%
Protagonist Therapeutics
Aug 31, 2026
Reiterated: Buy
Price Target: $165 → $170
Current: $138.43
Upside: +22.81%
Sionna Therapeutics
Aug 10, 2026
Downgraded: Hold
Price Target: n/a
Current: $3.60
Upside: -
Structure Therapeutics
Aug 7, 2026
Reiterated: Buy
Price Target: $113 → $110
Current: $21.19
Upside: +419.11%
Biomea Fusion
Aug 6, 2026
Reiterated: Buy
Price Target: $9 → $7
Current: $0.6001
Upside: +1,066.47%
Mirum Pharmaceuticals
Aug 6, 2026
Reiterated: Buy
Price Target: $146 → $137
Current: $80.39
Upside: +70.42%
Rhythm Pharmaceuticals
Aug 5, 2026
Reiterated: Buy
Price Target: $152 → $160
Current: $89.27
Upside: +79.23%
Annexon
Jul 21, 2026
Initiated Coverage: Sell
Price Target: $3
Current: $3.75
Upside: -20.00%
Madrigal Pharmaceuticals
Jul 17, 2026
Reiterated: Buy
Price Target: $745 → $739
Current: $434.24
Upside: +70.18%
Jun 30, 2026
Reiterated: Buy
Price Target: $55
Current: $9.75
Upside: +464.10%
May 14, 2026
Reiterated: Buy
Price Target: $14 → $11
Current: $2.12
Upside: +418.87%
May 14, 2026
Reiterated: Buy
Price Target: $170 → $150
Current: $45.15
Upside: +232.23%
May 13, 2026
Reiterated: Buy
Price Target: $12 → $11
Current: $3.47
Upside: +217.00%
May 13, 2026
Reiterated: Buy
Price Target: $26 → $25
Current: $1.87
Upside: +1,236.90%
May 12, 2026
Reiterated: Buy
Price Target: $61 → $86
Current: $48.50
Upside: +77.32%
May 7, 2026
Reiterated: Buy
Price Target: $25 → $28
Current: $7.65
Upside: +266.01%
Mar 12, 2026
Reiterated: Buy
Price Target: $8
Current: $1.29
Upside: +520.16%
Feb 17, 2026
Reiterated: Buy
Price Target: n/a
Current: $6.50
Upside: -
Oct 23, 2025
Reiterated: Buy
Price Target: $8 → $11
Current: $4.22
Upside: n/a
Oct 6, 2025
Reiterated: Buy
Price Target: $18
Current: $2.35
Upside: n/a
Oct 6, 2025
Reiterated: Buy
Price Target: $120 → $32
Current: $1.54
Upside: n/a
May 23, 2025
Reiterated: Buy
Price Target: $19
Current: $6.30
Upside: n/a
Apr 23, 2025
Reiterated: Hold
Price Target: n/a
Current: $16.64
Upside: n/a
May 12, 2023
Reiterated: Buy
Price Target: $24
Current: $30.86
Upside: n/a